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 Patients with acutely decompensated cirrhosis without
ACLF develop 3 different clinical courses.
 Patients with pre-ACLF develop ACLF within 90 days and
have high systemic inflammation and mortality.
 Patients with unstable decompensated cirrhosis suffer
from complications of severe portal hypertension.
 Patients with stable decompensated cirrhosis have less
frequent complications and lower 1-year mortality risk.
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Lay summary
Herein, we describe, for the first time, 3 dif-
ferent clinical courses of acute decom-
pensation (AD) of cirrhosis after hospital
admission. The first clinical course includes
patients who develop acute-on-chronic liver
failure (ACLF) and have a high short-term risk
of death – termed pre-ACLF. The second
clinical course (unstable decompensated cir-
rhosis) includes patients requiring frequent
hospitalizations unrelated to ACLF and is
associated with a lower mortality risk than
pre-ACLF. Finally, the third clinical course
(stable decompensated cirrhosis), includes
two-thirds of all patients admitted to hospi-
tal with AD – patients in this group rarely
require hospital admission and have a much
lower 1-year mortality risk.
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defined as the acute development of ascites, gastrointestinal
hemorrhage, hepatic encephalopathy, infection or any combi-
nation thereof, requiring hospitalization. The presence of organ
failure(s) in patients with AD defines acute-on-chronic liver
failure (ACLF). The PREDICT study is a European, prospective,
observational study, designed to characterize the clinical course
of AD and to identify predictors of ACLF.
Methods: A total of 1,071 patients with AD were enrolled. We
collected detailed pre-specified information on the 3-month
period prior to enrollment, and clinical and laboratory data at
enrollment. Patients were then closely followed up for 3 months.
Outcomes (liver transplantation and death) at 1 year were also
recorded.
Results: Three groups of patients were identified. Pre-ACLF pa-
tients (n = 218) developed ACLF and had 3-month and 1-year
mortality rates of 53.7% and 67.4%, respectively. Unstable
decompensated cirrhosis (UDC) patients (n = 233) required >−1
readmission but did not develop ACLF and had mortality rates of
21.0% and 35.6%, respectively. Stable decompensated cirrhosis
(SDC) patients (n = 620) were not readmitted, did not develop
ACLF and had a 1-year mortality rate of only 9.5%. The 3 groups
differed significantly regarding the grade and course of systemic
inflammation (high-grade at enrollment with aggravation during
follow-up in pre-ACLF; low-grade at enrollment with subsequent
steady-course in UDC; and low-grade at enrollment with sub-
sequent improvement in SDC) and the prevalence of surrogates
of severe portal hypertension throughout the study (high in UDC
vs. low in pre-ACLF and SDC).
Conclusions: Acute decompensation without ACLF is a hetero-
geneous condition with 3 different clinical courses and 2 major
pathophysiological mechanisms: systemic inflammation and
portal hypertension. Predicting the development of ACLF
remains a major future challenge.
ClinicalTrials.gov number: NCT03056612.
Lay summary: Herein, we describe, for the first time, 3 different
clinical courses of acute decompensation (AD) of cirrhosis after
hospital admission. The first clinical course includes patients
who develop acute-on-chronic liver failure (ACLF) and have a
high short-term risk of death – termed pre-ACLF. The second
clinical course (unstable decompensated cirrhosis) includes
patients requiring frequent hospitalizations unrelated to ACLF
and is associated with a lower mortality risk than pre-ACLF.
Finally, the third clinical course (stable decompensated
cirrhosis), includes two-thirds of all patients admitted to hospital
with AD – patients in this group rarely require hospital admis-
sion and have a much lower 1-year mortality risk.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Acute decompensation (AD) of cirrhosis is defined as the acute
development of ascites, hepatic encephalopathy, gastrointestinal
hemorrhage or bacterial infections or any combination thereof.1–3of Hepatology 2cirrhosis. The first episode of AD signals the transition from
compensated to decompensated cirrhosis.4 Decompensated
cirrhosis is characterized by recurrent episodes of AD. Finally,
recent data from the CANONIC study have shown that AD has 2
distinct clinical presentations, depending on the presence or
absence of organ failures and the grade of systemic inflamma-
tion.5–8 The presence of both organ failures and high-grade sys-
temic inflammation is the hallmark of acute-on-chronic liver
failure (ACLF), a syndrome associated with a very high 28-day
mortality rate, while AD is associated with moderate systemic
inflammation and a low 28-day mortality rate. Systemic inflam-
mation in AD and ACLF frequently develops in association with
exogenous precipitating events (mainly bacterial infections or
acute alcoholic liver injury). However, it might also be secondary
to translocation of intestinal bacterial immunogenic material to
the systemic circulation.9,10 Systemic inflammation may induce
organ dysfunction/failure via a direct immunopathological effect
on peripheral organs or via mitochondrial dysfunction, both of
which have been identified in decompensated cirrhosis.8
The CANONIC study was specifically designed to characterize
ACLF but did not provide detailed information on the clinical
context prior to and after ACLF and AD development. Yet, the
CANONIC study showed that patients with AD had very low
mortality rate (2%) at 28 days but a substantial mortality rate
(10%) at 90 days, suggesting a heterogeneity of clinical course in
patients with AD. Detailed information on this period is an
unmet medical need for the rational management of patients
with AD and the prevention of ACLF development.
To answer these questions, we designed the PREDICT study
(PREDICTing Acute-on-Chronic Liver Failure), the second
prospective large-scale observational investigation performed
by the European Association for the Study of the Liver
(EASL)-Chronic Liver Failure (CLIF) Consortium. It included 1,071
patients with cirrhosis hospitalized for the treatment of an
episode of AD without ACLF. The current article reports the
results of the first study derived from this investigation, the aim
of which was to characterize the clinical course and patho-
physiology of AD, and to predict the development of ACLF.
Patients and methods
Study oversight
The PREDICT study is a European, multicenter, prospective,
observational study performed in 48 hospitals. Each hospital had
a liver unit, specific ward(s) for liver patients and intensive care
facilities, and all of them had access to a liver transplantation
program. The study protocol (available with the full text of this
article) was approved by the institutional review board (IRB) at
each participating center. Patients were screened and enrolled
from March 2017 to July 2018. Written informed consent was
obtained from patients or their legal surrogates before enroll-
ment. An investigator was responsible for enrolling patients in
the study at each center, ensuring adherence to the protocol, and
completing the electronic case-report form. Data were continu-
ously monitored on-line by the Data Management Center of the020 vol. 73 j 842–854 843
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Fig. 1. Scheme of visits and collection of data and samples during the 6-month observational period. The 6-month period which included the 3-month
period prior to enrollment, the enrollment visit, and the 3-month follow-up period after enrollment. At enrollment patients were initially stratified into 2
groups based on the risk of ACLF development: high-risk group (CLIF-C AD-score >−50) and low-risk group (CLIF-C AD-score <50).
12 In the high-risk group, the
scheduled visits were performed at enrollment (visit 1) and 1, 4, 8 and 12 weeks after enrollment (visits 2–5). In the low-risk group, scheduled visits were
performed only at enrollment (visit 1) and week 1 (visit 2) and 12 (visit 5) after enrollment. Any patient of both groups developing ACLF within the follow-up
period received unplanned ACLF visits at the time of diagnosis of ACLF and 7 days later. Additional study visits were performed whenever a patient had to be
readmitted for any reason except ACLF (readmission visits) in the high-risk group only, but the number of readmissions was recorded in both groups. Finally, data
on liver transplantation or death and causes of death were prospectively collected 3, 6 and 12 months after enrollment in all patients. ACLF, acute-on-chronic liver
failure; CLIF-C AD, Chronic Liver Failure Consortium acute decompensation.
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and approved the final manuscript.
Patients
A total of 1,421 patients non-electively admitted for the treatment
of an episode of AD were eligible, of whom 148 patients met
exclusion criteria (Table S1), 202 patients presented with ACLF
and 1,071 patients were analyzed. Among these, 218 developed
AD for the first time, and the remaining 853 had a prior history of
AD. The diagnosis of cirrhosis was based on previous liver biopsy
findings or a composite of clinical signs and findings provided by
laboratory test results, endoscopy and ultrasonography. Diag-
nostic criteria for AD upon hospitalization were based on the
development of ascites, hepatic encephalopathy, gastrointestinal
hemorrhage, infection, or any combination of these. Importantly,
AD was not due to an isolated bacterial infection in any of the
enrolled patients. Diagnosis of ACLF during follow-up was per-
formed according to the CANONIC study criteria.7 Organ failure
and organ dysfunction were defined according to the CLIF
consortium (CLIF-C) organ failure (OF) score.11
Study design
Pre-specified clinical data, standard laboratory data and biolog-
ical samples for biobanking were obtained at enrollment and844 Journal of Hepatology 2sequentially during the follow-up visits (Fig. 1). The electronic
case-report form was designed to collect granularity in the
clinical data and the detailed queries answered remaining issues
in case of inconsistencies. Herein, only clinical and standard
laboratory data are analyzed.Data obtained at enrollment
Two categories of pre-specified information were obtained at
enrollment. The first category included general characteristic and
demographic data, specific data related to the AD episode at
enrollment, results of physical examination and standard labo-
ratory analysis, including differential white-cell blood count
(WBC) and C-reactive protein (CRP) levels, as markers of
systemic inflammation. Cultures were routinely performed in
patients with suspected bacterial infections.
The second category of pre-specified data was related to the
past medical history and included: a) the timepoint of the onset
of decompensated cirrhosis (as defined by the first episode of
AD); b) the complications of AD occurring within the last 3
months prior to enrollment; c) treatment of complications
(including prior transjugular portosystemic shunt stent [TIPS]
and its indication); and d) any hospitalization during the last
3 months prior to enrollment. Data regarding onset of decom-
pensated cirrhosis could be obtained in 612 patients. Data020 vol. 73 j 842–854
regarding the occurrence of ascites, gastrointestinal hemorrhage,
hepatic encephalopathy, bacterial infections and hospitalizations
within the last 3-month period prior to enrollment were
obtained in 860, 796, 793, 791 and 831 patients, respectively.
Data obtained during follow-up
After enrollment, patients were prospectively followed-up for a
period of 3months. The scheme of visits and collection of data and
samples at enrollment and during the 3-month follow-up period
after enrollment is indicated in Fig. 1. Finally, data on liver trans-
plantation or death and causes of death were prospectively
collected 3, 6 and 12 months after enrollment in all patients.
Defining the 6-month observational period
Of note, according to the pattern of data collection described
earlier, we defined a 6-month observational period, which
included the 3-month period prior to enrollment, the enrollment
visit and the 3-month follow-up period after enrollment (Fig. 1).
Amendment to the initial study protocol
During the first 8 months of the study, 720 patients were
consecutively enrolled, and used for prevalence calculations.
Subsequently, since the number of patients developing ACLF was
low, we amended the study protocol to enroll only high-risk
patients. After IRB approval of this amendment, the last 351
patients were enrolled in the study.
Statistical analysis
Patient stratification
Patient stratification was performed based on the clinical course
during the3-month follow-upperiod for several reasons: i) themain
objective of the studywas the characterization of the clinical course
after enrollment; ii) a preliminary analysis of an incomplete set of
consecutive patients included in the PREDICT study showed that AD
consisted of a single complication (either ascites, encephalopathy or
gastrointestinal hemorrhage) in only 50% of patients. The remaining
patients had 2 or 3 simultaneous complications, making stratifica-
tionbasedoncomplicationsatenrollmentextremelycomplex. iii) By
contrast, stratification of patients based on ACLF development (yes
or no) and clinical course profile (unstable vs. stable, among ACLF-
free patients) during the 3-month follow-up was simpler and
more appropriate for addressing the main objective of the study.
Therefore, our patients were stratified into 3 groups for data
analysis: i) pre-ACLF group: patients who developed ACLF within
90 days of enrollment; ii) unstable decompensated cirrhosis
(UDC) group: patients who experienced at least 1 hospital
readmission, but without ACLF development within the 90-day
follow-up period; and iii) stable decompensated cirrhosis (SDC)
group: patients without ACLF development or readmissions
within the 90-day follow-up period.
Because bacterial infections are major precipitants of AD and
ACLF, and systemic inflammation is the hallmark of AD and ACLF,
infections and systemic inflammation were considered in detail
when characterizing these groups.
Data analysis
Discrete variables are summarized as counts (percentages) and
continuous variables as mean ± SD. Non-normally distributed
variables are summarized as median (IQR) and were log-
transformed for some statistical analyses and for graphical
comparisons. In univariate statistical comparisons, the chi-Journal of Hepatology 2square test was used for categorical variables, whereas the
Student’s t test or analysis of variance were used for normally
distributed continuous variables and the Wilcoxon signed-rank
test or the Kruskal-Wallis test were used for non-normally
distributed continuous variables. In all statistical analyses,
significance was set at p <0.05.
Tools to predict ACLF development
For the prediction of ACLF development during the 90-day
follow-up period, the CLIF-C ACLF development score (CLIF-C
ACLF-D score) was fitted according to the TRIPOD recommen-
dations (see TRIPOD checklist). There were no missing data in
most potential predictors of ACLF development at enrollment,
except for serum albumin and plasma CRP levels, whose values
were not available, respectively, in 5%, 9% and 8% of patients from
the pre-ACLF, UDC, and SDC groups and in 20%, 13% and 11% of
patients from the 3 groups (Table S2). Therefore, for multivariate
analysis, we assumed that these missing values could be
considered at random and carried out a multiple imputation
based on a mixed model including all potential predictors
significantly associated with ACLF in the univariate analysis.13
We used the proportional-hazards model for competing risks
proposed by Fine and Gray to identify the best subset of inde-
pendent predictors associated with the onset of ACLF and to
develop a new predictive score (the CLIF-C ACLF-D score).14 Liver
transplantation and death could be considered as ‘competing’
events in the competing risks model. The initial model included
the most relevant characteristics at enrollment found to be
significantly associated (both clinically and statistically) with
ACLF development at 3 months in the univariate analysis
(Table S3). In the final CLIF-C ACLF-D score model, the best subset
of independent predictors was selected based on a stepwise
forward procedure with p-in <0.05 and p-out <0.10 for the
change in model log-likelihood (Table S4). The coefficients
estimated for each predictor were used as relative weights to
compute the score.
Because the PREDICT study is the only thorough investigation
on the factors leading to ACLF, no other cohort could be used for
external validation. As a result, we had to carry out a random
split-sample derivation and validation processes for the new
score. The subset of patients used to derive the score included
two-thirds of patients (n = 707) randomly selected from each
patient group. The internal score validation was performed on
the remaining third of patients (n = 364) and compared the
predictive ability of the CLIF-C ACLF-D score with those of the
CLIF-C AD score, MELD, MELD-sodium and Child-Pugh scores by
estimating the corresponding Harrel’ C-indexes and 95% CIs both
in the derivation and validation sets.
As a complementary tool to predict ACLF development, a de-
cision tree model was fitted using the 980 patients with
information about the development of ACLF. Patients, who died or
were transplantedwithout presentingACLF before 3monthswere
excluded. The clinical variables selected for the model were the
independent predictors of ACLF development obtained in the
multivariate analysis for the CLIF-C ACLF-D score. The decision
tree algorithm selected the most relevant of these clinical
variables, their positionwithin the decision tree and their optimal
cut-off values. The model was fitted using R software (version
3.6.3) rpart packagewith settingsminsplit = 10 andmaxdepth = 5.
Also, the complexity parameter was set by default to 0.01. Model
parameterswere estimated using the function tune.rpart from the020 vol. 73 j 842–854 845
Table 1. Patient characteristics prior to, at, and after enrollment.
Characteristic
Pre-ACLF (n = 218) UDC (n = 233) SDC (n = 620) p value
Age, years, mean ± SD 61.1 ± 10.0 60.9 ± 10.6 57.9 ± 11.0a <0.001
Female sex, n (%) 70 (32.1) 74 (31.8) 200 (32.3) 0.990
Etiology of cirrhosis, n (%)
Alcohol 107 (49.1) 143 (61.4)b 346 (55.9) 0.032
HCV 14 (6.4) 12 (5.2) 41 (6.6) 0.727
Alcohol and HCV 10 (4.6) 8 (3.4) 33 (5.3) 0.506
Non-alcoholic steatohepatitis 16 (7.3) 17 (7.3) 48 (7.8) 0.965
Other etiologies 70 (32.1) 51 (21.9)b 150 (24.2)b 0.028
Events prior to enrollment, n (%)
Ascites 130 (66.7) 122 (65.9) 229 (47.7)a <0.001
Hepatic encephalopathy 46 (25.4) 54 (31.4) 75 (17.1)a <0.001
Gastrointestinal hemorrhage 17 (9.6) 29 (17.1)b 62 (13.9) 0.125
Any hospitalization 106 (56.7) 119 (65.0) 210 (45.6)a <0.001
Data at enrollment
Clinical data, organ failures and organ dysfunctions, n (%)
Ascites 173 (79.4) 170 (73.0) 415 (66.9)b 0.002
Hepatic encephalopathy 65 (29.8) 73 (31.3) 168 (27.1) 0.428
Gastrointestinal hemorrhage 16 (7.3) 39 (16.7)b 97 (15.6)b 0.005
No organ failure or dysfunction 50 (22.9) 80 (36.5)b 291 (46.9)a <0.001
Liver failure 29 (13.3) 11 (4.7)b 30 (4.8)b <0.001
Liver dysfunction 51 (23.4) 36 (15.5)b 84 (13.5)b 0.003
Circulatory dysfunction 20 (9.2) 43 (18.5)b 50 (8.1)c <0.001
Renal dysfunction 51 (23.4) 17 (7.3)b 40 (6.5)b <0.001
Coagulation failure 8 (3.7) 4 (1.7) 7 (1.1)b 0.050
Coagulation dysfunction 29 (13.3) 19 (8.2) 46 (7.4)b 0.029
Brain failure 4 (1.8) 4 (1.7) 16 (2.6) 0.676
Brain dysfunction 59 (27.1) 67 (28.8) 144 (23.2) 0.197
Respiratory dysfunction 10 (4.6) 8 (3.4) 29 (4.7) 0.722
Main reason for hospitalization
Ascites 105 (48.4) 106 (45.5) 267 (43.1) 0.382
Hepatic encephalopathy 29 (13.4) 34 (14.6) 82 (13.2) 0.870
Gastrointestinal hemorrhage 13 (6.0) 37 (15.9)b 110 (17.7)b <0.001
Bacterial infection 32 (14.7) 27 (11.6) 84 (13.5) 0.603
Other 38 (17.5) 29 (12.4) 77 (12.4) 0.147
Biomarkers of systemic inflammation, median (IQR)
White-cell count, ×109/L 7.2 (4.9–9.8) 6.1 (4.3–8.5)b 6.0 (4.2–8.7)b 0.002
Serum C-reactive protein, mg/L 23 (11–41) 16 (8–35)b 15 (6–36)b <0.001
Measurements estimating organ function
Serum bilirubin, mg/dl, median (IQR) 3.9 (1.9–9.0) 2.6 (1.3–5.4)b 2.3 (1.4–4.5)b <0.001
Serum albumin, g/dl, mean ± SD 2.7 ± 0.7 2.8 ± 0.6 3.0 ± 0.6a <0.001
INR, median (IQR) 1.6 (1.4–1.9) 1.4 (1.3–1.7)b 1.4 (1.2–1.7)b <0.001
Serum creatinine, mg/dl, median (IQR) 1.1 (0.8–1.5) 0.9 (0.7–1.2)b 0.8 (0.7–1.1)a <0.001
Plasma sodium, mEq/L, mean ± SD 134 ± 6 135 ± 5 136 ± 5a <0.001
Severity scores, mean ± SD
Child-Pugh 9.8 ± 1.8 9.2 ± 1.7b 8.7 ± 1.8a <0.001
MELD 19 ± 5 16 ± 5b 15 ± 5a <0.001
MELD-sodium 23 ± 5 19 ± 5b 18 ± 5a <0.001
CLIF-C AD 57 ± 8 53 ± 8b 50 ± 8a <0.001
Data after enrollment
Mortality rates, n (%)
90-day mortality rate 117 (53.7) 49 (21.0) –
1-year mortality rate 147 (67.4) 83 (35.6) 59 (9.5)
Main causes of death, n (%)
ACLF 130 (88.4) 25 (30.1)b 29 (49.2)a <0.001
Hypovolemic shock 4 (2.7) 14 (16.9)b 3 (5.1)c <0.001
Other causes of death 6 (4.1) 15 (18.1)b 15 (25.4)b <0.001
Unknown 7 (4.8) 29 (34.9)b 12 (20.3)b <0.001
Liver transplantation within 12 months after enrollment 33 (15.1) 39 (16.7) 73 (11.8) 0.125
(continued on next page)
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Table 1. (continued)
Characteristic
Pre-ACLF (n = 218) UDC (n = 233) SDC (n = 620) p value
Data after enrollment
Indicators of severe portal hypertension, n (%)
TIPSd 18 (8.3) 33 (14.2)b 63 (10.2) 0.107
TIPS for gastrointestinal hemorrhage 4 (1.8) 12 (5.4) 26 (4.2) 0.145
Any episode of gastrointestinal hemorrhaged 48 (22.0) 76 (32.6)b 155 (25.0)c 0.016
p values were obtained using chi-square test.
ACLF, acute-on-chronic liver failure; CLIF-C AD, Chronic Liver Failure Consortium acute decompensation; INR, international normalized ratio; MELD, model for end-stage liver
disease; SDC, stable decompensated cirrhosis; TIPS, transjugular intrahepatic portosystemic shunt; UDC, unstable decompensated cirrhosis.
aSignificantly different from the pre-ACLF group and UDC groups.
bSignificantly different from the pre-ACLF group.
cSignificantly different from the UDC group.
dAt any time of the 6-month observational period, this being defined by the 3 months prior to, and the 3 months as of enrollment.R package e1071, to select the best decision tree model, according
to accuracy, sensitivity and specificity. A decision tree plot was
generated based on the model fitted. A 10-Fold cross validation
was used to reduce over-fitting and to assess the discriminative
ability of the model, by estimating the corresponding sensitivity
and specificity of the model and computing the area under the
receiver-operating-characteristic curve (AUC).Results
Heterogeneity of the clinical course of AD
Clinical course of patients with AD
As expected, the pre-ACLF group, which included 218 patients
who developed ACLF during the 3-month follow-up period after
enrollment, had the highest 3-month and 1-year mortality rates
(53.7% and 67.4%, respectively) (Table 1). Twenty-two patients
with pre-ACLF were transplanted after ACLF developed within
the 3-month follow-up period. The 233 patients included in the
UDC group, who did not develop ACLF, but who died or requiredPre-ACLF group (n = 218)
UDC group (n = 233)
SDC group (n = 620)
0 30 60 90
Infections
ACLF
Death
Days
Fig. 2. Density curves of events during the 3-month follow-up period after
enrollment in patients with pre-ACLF, UDC and SDC. The zero timepoint
corresponds to enrollment into the study. Bacterial infections are represented
in red, ACLF in green, and deaths in blue. ACLF, acute-on-chronic liver failure;
SDC, stable decompensated cirrhosis; UDC, unstable decompensated cirrhosis.
Journal of Hepatology 2at least 1 hospital readmission within the 3-month follow-up
period, had 3-month and 1-year mortality rates of 21.0% and
35.6%, respectively; 177 of these patients required 1 readmission,
32 patients 2 readmissions, and 17 patients >−3 readmissions.
Fourteen patients with UDC were transplanted after readmission
for an AD episode within the 3-month follow-up period. Finally,
the 620 patients included in the SDC group, who did not develop
ACLF, require hospital readmission, nor die during the 3-month
follow-up period after enrollment, showed very low mortality
(9.5%) within the 1-year follow-up period after enrollment.
Among the 720 patients consecutively enrolled during the first
8 months after the onset of the study, 425 (59%) were in SDC
group. Twenty-eight patients with SDC were transplanted from
the waitlist without ACLF or a new episode of AD within the
3-month follow-up period.
The clinical course of patients with pre-ACLF was character-
ized by a huge density of bacterial infections, episodes of ACLF
and death, which are summarized as events (Fig. 2). A total of 120
patients (55% of this group) developed ACLF during the first
hospitalization and 98 developed the syndrome from first
discharge to the end of the 3-month follow-up period. The bac-
terial infection density curve chronologically preceded the ACLF
density curve, and both curves preceded the mortality density
curve, supporting a cause to effect relationship between the 3
events. The extreme proximity between the bacterial infection
and ACLF density curves reflects that ACLF is a hyperacute process
with a very short time period between precipitating events and
the onset of the syndrome. Fig. 3A shows the cumulative rate of
weekly occurrence of ACLF during the first 90 days after enroll-
ment of patients with pre-ACLF. Fig. 3B shows that using the 90th
day after enrollment as a landmark, the cumulative incidence of
death 1 year after enrollment was also higher among patients
assigned to the pre-ACLF group than among those assigned to 1 of
the other 2 groups. The density of events in the UDC group was
remarkably lower than the density of events in the pre-ACLF
group. Although this feature was mainly due to the lack of ACLF
episodes in the UDC group, the density of bacterial infections and
deaths were also lower. Finally, although the density of bacterial
infections at first presentation in the SDC group was as high as in
the UDC group, it was remarkably lower during the rest of the
3-month follow-up period.
There were no significant differences between the 3 groups of
patients regarding the etiology of cirrhosis (Table 1), prevalence
of active alcoholism (26.6%, 23.2% and 27.6%, respectively) or
presence of hepatocellular carcinoma (within Milan criteria) at
enrollment (5.4%, 6.5% and 3%, respectively). Moreover, there was020 vol. 73 j 842–854 847
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Fig. 3. Cumulative rates of ACLF and death. (A) Cumulative rate of ACLF per
week during the 90-day follow-up period in patients with pre-ACLF. (B) Cu-
mulative incidence of death between the 90-day (landmark) and 1 year after
enrollment in patients with pre-ACLF, UDC and SDC. ACLF, acute-on-chronic
liver failure; SDC, stable decompensated cirrhosis; UDC, unstable decom-
pensated cirrhosis.
Research Article Cirrhosis and Liver Failureno between-group difference in the number of patients with
alcohol cessation (52 [23.9%] patients for pre-ACLF, 46 [19.7%] for
UDC, and 146 [23.6%] for SDC; p = 0.456) and the number of
those receiving HCV therapy (4 [1.9%] patients for pre-ACLF, 3
[1.3%] for UDC, and 14 [2.3%] for SDC; p = 0.650).
Duration of the decompensated phase of cirrhosis
The time-course density curves of liver transplantation or death
in the 234 patients developing these events are shown in Fig. 4A.
Time zero in this figure represents the onset of decompensated
cirrhosis. Therefore, this analysis estimates the between-group
differences in the length of the entire phase of decompensated
cirrhosis. The pre-ACLF density curve preceded the UDC density
curve, and both curves preceded the SDC density curve. These
findings clearly indicate that ACLF development in patients with
pre-ACLF significantly reduced the duration of the decom-
pensated phase of the disease. Confirming these observations,
the median time from the onset of decompensated cirrhosis to
death or liver transplantation was 12 months (IQR 5.2–25.8) in
patients with pre-ACLF, 14 months (9.6–24.3) in patients with
UDC (p = 0.01 vs. patients with pre-ACLF), and 20 months
(11.4–41.3) in patients with SDC (p = 0.04 vs. patients with UDC).
These findings are confirmed by comparing individual values of
the time period between the onset of decompensated cirrhosis
and liver transplantation, death or end of follow-up between the
3 groups (Fig. 4B). Considering the between-group differences in
mortality, the distinct duration of the decompensation phase
would have been even more marked if follow-up had been
longer than 1 year.848 Journal of Hepatology 2Prevalence and severity of bacterial infections
Table 2 provides information about infections during the 3
months before enrollment, at enrollment and during the 3
months after enrollment. Overall, 178 (22.4%) out of the 796
patients with data developed at least 1 bacterial infection during
the 3-month period prior to enrollment. Of the 1,071 patients
included in the analysis, 29.3% (n = 314) and 24% (n = 257) had
infections at enrollment and during the 3-month follow-up
period, respectively. These 571 patients with infections at
enrollment or during follow-up (53.3%) presented a total of 674
infections.
Considering bacterial infections, Table 2 shows that the
distinctive features of patients with pre-ACLF relative to patients
of the 2 other groups included a higher proportion of patients
with at least 1 infectious episode during the 6-month
observational period (see also Fig. 4C); higher proportion of pa-
tients with sepsis at enrollment and during follow-up; higher
proportion of patients with pneumonia during follow-up; and a
higher proportion of patients receiving therapeutic antibiotics; all
these differences being significant. During follow-up, the pro-
portion of patients with community-acquired infection was
significantly lower among patients with pre-ACLF than among the
2 other groups (Table 2). These findings are consistent with
higher prevalence and severity of bacterial infections in the
pre-ACLF group. At any time, the proportion of patients with in-
fections caused by multi-drug-resistant bacteria was significantly
higher between the pre-ACLF group and the UDC group (Table 2).
Clinical features prior to enrollment
By definition, patients with pre-ACLF and UDC exhibited greater
clinical instability during the first 3 months after enrollment
than patients with SDC. However, their clinical courses were also
more unstable within the 3-month period prior to enrollment, as
indicated by the significantly higher frequency of bacterial in-
fections, ascites or hepatic encephalopathy and, consequently,
hospital admissions in these groups of patients (Tables 1 and 2).
Clinical features and laboratory data at enrollment and
during follow-up
Markers of systemic inflammation across groups
The WBC count and the CRP levels were significantly higher at
enrollment in patients with pre-ACLF than in patients from the
other 2 groups (Table 1). In contrast, there were no significant dif-
ferences in these biomarkers between patients with UDC and SDC.
We compared the CRP levels and WBC measured at enroll-
ment in patients with SDC, UDC and pre-ACLF, with those
measured at the time of follow-up diagnosis of ACLF in 176
patients from the pre-ACLF group (including 103 patients with
ACLF-1, 52 with ACLF-2, and 21 with ACLF-3), and those
measured in a control group of 34 patients with compensated
cirrhosis (no prior history of AD) (Fig. 4D) previously
described.5,6 Of note, the last 2 groups were included to facilitate
the comparison of systemic inflammation throughout the whole
spectrum of cirrhosis. There was a progressive increase in the
grade of systemic inflammation across the different groups.
We also performed within-group comparisons of the levels of
inflammatory markers measured at enrollment vs. those
measured during follow-up (Table 3). The follow-up timepoint
was the time of diagnosis of ACLF for the pre-ACLF group, while
for the other 2 groups of patients, it was the last measurement
prior to liver transplantation, or death, or the end of the 3-month020 vol. 73 j 842–854
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Fig. 4. Liver transplantation or death, as well as surrogates of systemic inflammation and portal hypertension in patients with pre-ACLF, UDC and SDC. (A)
Density curves of liver transplantation or death during the 1-year follow-up period after enrollment in patients with pre-ACLF (in red), UDC (in blue) and SDC (in
green) taking the zero-point as the onset of acute decompensation. The median time (IQR) from the onset of clinically decompensated cirrhosis (as defined by the
date of first the episode of acute decompensation) to death or liver transplantation (duration of the decompensated phase of cirrhosis) was significantly shorter in
patients with pre-ACLF than in those with UDC, and in patients with UDC than in those with SDC. p values were obtained using Mann-Whitney U test. (B)
Individual time period between the onset of decompensated cirrhosis and liver transplantation, death or the end of the 1-year follow-up period after enrollment
in the 3 groups of patients. For clarity, the figure does not include patients with values over the 75% IQR. Differences between groups were highly significant (p
<0.001). p values were obtained using Kruskal-Wallis test. (C) The percentage of patients developing at least 1 bacterial infection during the 6-month obser-
vational period in patients with pre-ACLF, UDC and SDC. p values were obtained using chi-square test. (D) Plasma levels of CRP (median and 75% CI) in a control
group of 34 patients with compensated cirrhosis (CC, no prior history of AD), SDC, UDC, pre-ACLF and ACLF. Patients with CC were studied previously.5,6 The ACLF
group includes 176 patients from the pre-ACLF group who develop ACLF during the 3-month follow-up period. Samples for PCR measurements in these patients
were obtained at the time of ACLF development, p values were obtained using Kruskal-Wallis test. (E) Serum concentration of C-reactive protein in 134 patients
without prior history of AD who were enrolled only for ascites, encephalopathy or gastrointestinal hemorrhage. p values were obtained using Kruskal-Wallis test.
(F) Percentage of patients presenting at least one surrogate of severe portal hypertension during the 6-month observational period in the Pre-ACLF, UDC and SDC
groups. P values were obtained using chi-square test. ACLF, acute-on-chronic liver failure; AD, acute decompensation; CC, compensated cirrhosis; CRP, C-reactive
protein; SDC, stable decompensated cirrhosis; UDC, unstable decompensated cirrhosis.follow-up period. Within each group, there was a close
relationship between changes in inflammatory markers and the
clinical course (Table 3). Progression of AD to ACLF in the pre-
ACLF group occurred in the setting of a significant increase in
WBC count and serum concentration of CRP. In patients with
UDC there were no significant changes in WBC count and a small,
but significant decrease in CRP, suggesting minor improvement
of systemic inflammation. Finally, patients with SDC had a
significant reduction in WBC and PCR.Association between systemic inflammation and complications that
define AD
In order to assess the association between systemic inflammation
and the 3 major complications that define AD, we explored 134
patients who had no prior history of AD and were enrolled only
for ascites (n = 99), encephalopathy (n = 14) or gastrointestinal
hemorrhage (n = 21). The median (IQR) levels of plasma CRP wasJournal of Hepatology 2remarkably higher (p <0.002) in patients with ascites (23.4
[12.5–38.0]) than in those with encephalopathy (11.0 [4.4–21.6])
and gastrointestinal hemorrhage (5.0 [3.0–22.4]) (Fig. 4E).Organ function and scores
The prevalence of liver failure, liver dysfunction and renal
dysfunction (as defined by the CLIF-C OF score11) at enrollment
was significantly higher among patients with pre-ACLF group
than among those with UDC and SDC (Table 1). Moreover, lab-
oratory measurements estimating liver and renal function at
enrollment were significantly more impaired among patients
with pre-ACLF than among those with UDC and SDC, suggesting
that a significant deterioration of organ function existed prior to
enrollment in patients with pre-ACLF.
CLIF-C AD and MELD-sodium scores significantly worsened
during the progression of pre-ACLF to ACLF and improved in020 vol. 73 j 842–854 849
Table 2. Characteristics of infections at enrollment and during the 90-day follow-up period.
Characteristic Pre-ACLF
(n = 218)
UDC
(n = 233)
SDC
(n = 620)
p value
Number of patients with infections n (%)*
3 months prior to enrollment 58 (31.0) 45 (26.5) 75 (17.1)a <0.001
At enrollment 74 (33.9) 61 (26.2) 178 (28.7) 0.176
3 months after enrollment 106 (48.6) 83 (35.6)b 68 (11.0)a <0.001
Throughout the 6-month observational period 158 (72.5) 133 (57.1)b 251 (40.5)a <0.001
Infections at enrollment
Number of infections 83 67 189
Site of infection, n/N (%)*
Urinary tract 19/83 (22.9) 15/67 (22.4) 44/189 (23.2) 0.985
Spontaneous bacterial peritonitis 18/83 (21.7) 13/67 (19.4) 26/189 (13.8) 0.232
Pneumonia 10/83 (12.0) 14/67 (20.9) 24/189 (12.8) 0.213
Spontaneous bacteremia 9/83 (10.8) 5/67 (7.5) 9/189 (4.8) 0.184
Cellulitis 4/83 (4.8) 6/67 (9.0) 18/189 (9.6) 0.414
Suspected infections 6/83 (7.2) 8/67 (11.9) 35/189 (18.6)b 0.040
Otherc 17/83 (20.5) 6/67 (9.0) 32/189 (17.0) 0.150
Severity of infection, n/N (%)*
Community-acquired 52/83 (62.6) 35/67 (52.2) 149/189 (78.8)a <0.001
Health-care- or hospital-acquired 31/83 (37.4) 32/67 (47.8) 40/189 (21.2)a <0.001
Sepsis 26/83 (31.3) 11/67 (16.4)b 28/189 (15.1)b 0.005
Infection caused by MDR bacteria 6/83 (7.2) 3/67 (4.9) 18/189 (10.3) 0.379
Infections during the 3-month follow-up period
Number of infections 140 117 76
Site of infection, n/N (%)*
Urinary tract 35/140 (25.0) 31/117 (26.5) 22/76 (28.9) 0.821
Spontaneous bacterial peritonitis 21/140 (15.0) 24/117 (20.5) 5/76 (6.6)c 0.030
Pneumonia 27/140 (19.3) 10/117 (8.5)b 10/76 (13.2) 0.047
Spontaneous bacteremia 10/140 (7.1) 9/117 (7.7) 2/76 (2.6) 0.319
Cellulitis 6/140 (4.3) 8/117 (6.8) 4/76 (5.3) 0.665
Suspected infections 16/140 (11.4) 13/117 (11.1) 16/76 (21.1) 0.091
Otherc 25/140 (17.9) 22/117 (18.8) 17/76 (22.4) 0.717
Severity of infection, n/N (%)*
Community-acquired 14/140 (10.0) 15/117 (12.8)b 15/76 (19.7)b 0.129
Health-care- or hospital-acquired 126/140 (90.0) 102/117 (87.2) 61/76 (80.3)b 0.129
Sepsis 70/140 (50.0) 21/117 (18.1)b 4/76 (5.3)a <0.001
Infection caused by MDR bacteria 44/140 (33.8) 29/117 (28.2) 11/76 (16.2)b 0.031
p values were obtained using chi-square, * is calculated over the available data, no imputation was included in the table.
ACLF, acute-on-chronic liver failure; MDR, multidrug resistant; SDC, stable decompensated cirrhosis; UDC, unstable decompensated cirrhosis.
aSignificantly different from the pre-ACLF group and UDC groups.
bSignificantly different from the pre-ACLF group.
cOther: catheter-related infection, cholecystitis, cholangitis, secondary peritonitis, pseudomembranous colitis, other gastrointestinal infection.
Research Article Cirrhosis and Liver Failurepatients with SDC (Table 3). Scores also improved in patients
with UDC, although to a lesser extent than in patients with SDC.
Increased prevalence of features suggesting severe portal
hypertension in patients with UDC
Whereas severe systemic inflammation and organ failure or
dysfunction were the most prominent features in patients from
the pre-ACLF group, surrogates of severe portal hypertension
were the hallmark of patients with UDC. First, the prevalence of
circulatory dysfunction at enrollment (Table 1) and of gastroin-
testinal hemorrhage within the 6-month observational period
(32% vs. 22% [p = 0.01] and 25% [p = 0.03], respectively) were
significantly higher among patients with UDC than among those
with pre-ACLF and those with SDC. Second, the percentage of
patients who received TIPS during this period was also higher
in the UDC group than in the other 2 groups (14.2% vs. 8.3%
[p = 0.04] and 10.2% [p = 0.1], respectively). Finally, the preva-
lence of hypovolemic shock as the main cause of death was
6- and 3-times higher in patients with UDC group (16.9%) than in
those with pre-ACLF (2.7%; p <0.001) and SDC (5.1%; p <0.001).
Fig. 4F shows that the percentage of patients with at least 1
surrogate of severe portal hypertension was significantly higher850 Journal of Hepatology 2in patients with UDC (44.6%) than in patients with pre-ACLF
(27.1%) and SDC (31.3%).
Tools to predict development of ACLF
The CLIF-C ACLF-D score was developed to predict, at the time
of hospital admission, the probability of a patient with AD
developing ACLF during the following 3 months. The initial
model was fitted including all the main characteristics at
enrollment found to be associated with the development of
ACLF in the univariate analysis (Table S3). Patients age (years),
presence of ascites, WBC count (×109/L), serum albumin (g/dl),
serum bilirubin (mg/dl), and serum creatinine (mg/dl) at study
enrollment were subsequently identified as the best subset of
independent predictors in the final model (Table S4) and their
coefficients were used as relative weight to compute the cor-
responding score. The equation for CLIF-C ACLF-D score is as
follows:
CLIF-C ACLF-D score = ((0.03 × Age) + (0.45 × Ascites) + (0.26 ×
ln(WBC)) − (0.37 × Albumin) + (0.57 × ln(Bilirubin)) + (1.72 ×
ln(Creatinine)) + 3 × 10.
The prognostic accuracy of CLIF-C ACLF-D score (Fig. 5A) was
higher than those of CLIF-C AD, MELD, MELD-sodium and Child-020 vol. 73 j 842–854
Table 3. Inflammatory markers and severity scores at enrollment and during the 90-day follow-up period.
Enrollment Follow-up p value
Pre-ACLF (n = 218)
Blood biomarkers of systemic inflammation, median (IQR)
White-cell count, ×109/L 7.2 (4.9–9.8) 8.3 (5.7–12.9) <0.001
Serum C-reactive protein, mg/L 23 (11–41) 29 (14–52) 0.033
Severity scores, mean ± SD
MELD-sodium 23 ± 5 28 ± 6 <0.001
CLIF-C AD 57 ± 7 64 ± 9 <0.001
Unstable decompensated cirrhosis (n = 233)
Blood biomarkers of systemic inflammation, median (IQR)
White-cell count, ×109/L 6.1 (4.3–8.5) 5.9 (4.0–8.0) 0.343
Serum C-reactive protein, mg/L 16 (8–35) 12 (5–26) 0.004
Severity scores, mean ± SD
MELD-sodium 19 ± 5 18 ± 6 0.006
CLIF-C AD 53 ± 7 51 ± 8 0.031
Stable decompensated cirrhosis (n = 620)
Blood biomarkers of systemic inflammation, median (IQR)
White-cell count, ×109/L 6.0 (4.2–8.7) 5.4 (3.9–7.3) <0.001
Serum C-reactive protein, mg/L 15 (6–36) 8 (4–17) <0.001
Severity scores, mean ± SD
MELD-sodium 18 ± 5 16 ± 5 <0.001
CLIF-C AD 50 ± 8 48 ± 7 <0.001
p values were obtained using the Wilcoxon signed-rank test or the Student’s t test where appropriate.
ACLF, acute-on-chronic liver failure; CLIF-C AD, Chronic Liver Failure Consortium acute decompensation; MELD, model for end-stage liver disease.
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Fig. 5. Predictive ability of the CLIF-C ACLF-D score. (A) Comparison between the predictive ability of the CLIF-C ACLF-D score with those of the CLIF-C AD,
MELD, MELD-sodium and Child-Pugh scores using Harrel’ C-indexes and 95% CIs both in the derivation and validation sets. (B) Decision tree plot for the prediction
of ACLF development during the 90-day follow-up period after enrollment. Each node shows the percentage of patients classified and their probability of ACLF
development within the 90-day follow-up period after enrollment (also represented by the colors and color intensity). The blue color represents a probability of
ACLF development >0.5. The green color represents a probability of ACLF development ACLF <0.5. The intensity of the color represents the estimated probability
value. The upper node (root node) represents the entire population of patients (980 patients, 100%) included in the analysis and its corresponding probability of
ACLF development before entering the model (0.22). Each node includes the estimated probability of subsequent subsets of patients. ACLF, acute-on-chronic liver
failure; CLIF-C ACLF-D, Chronic Liver Failure Consortium acute-on-chronic liver failure development; CLIF-C AD, Chronic Liver Failure Consortium acute
decompensation; MELD, model for end-stage liver disease.
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Research Article Cirrhosis and Liver FailurePugh scores in the derivation set. In the validation set, the CLIF-C
ACLF-D showed a similar accuracy but smaller differences with
regards to the other scores. Therefore, we were unable to design
a new score to predict ACLF development more accurately than
the traditional clinical scores.
The most relevant clinical variable selected by the decision
tree model was creatinine, with a threshold of 1.3 mg/dl (Fig. 5B).
Bilirubin, albumin, age and WBC were also selected to
subsequently discriminate patients. The terminal nodes with a
probability of ACLF higher than 0.5, classifying patients likely to
develop ACLF, included 14.1% of the patients. The model achieved
a discriminating ability (AUC) of 0.76 (0.72–0.79), with high
specificity (95%) but low sensitivity (38%), indicating an
important misclassification among those patients who actually
developed ACLF.Discussion
The most noteworthy finding of the current study was the
identification of 3 different clinical courses with distinct patho-
physiology and prognosis in patients hospitalized for the treat-
ment of an episode of AD. These 3 clinical courses were unrelated
to the etiology of cirrhosis, or to active alcoholism in patients
with alcohol-related cirrhosis, indicating that they were largely
dependent on other mechanisms.
The 3 distinct types of clinical courses coincided with specific
changes in the grade of systemic inflammation. Patients with
pre-ACLF showed significantly higher grade of systemic
inflammation at enrollment than patients with UDC and SDC. By
contrast, there was no significant difference in systemic
inflammation between patients with UDC and SDC. Moreover,
whereas the levels of inflammatory markers increased signifi-
cantly during follow-up, accompanying the progression of AD to
ACLF in patients with pre-ACLF, they decreased intensely in
patients with SDC, while they did not show clear changes in
patients with UDC. Therefore, a distinct progression of systemic
inflammation is likely a major pathogenetic mechanism un-
derlying the 3 clinical courses of patients with AD. This finding
is a key feature in the new comprehensive hypothesis for AD
presented in the current article.
Thus, patients with SDC developed the index episode of AD in
the context of moderate systemic inflammation. In addition,
systemic inflammation decreased rapidly and remained at low
intensity during the 3-month follow-up. Probably due to this, all
patients recovered from the index episode of AD, most presented
a long-term relatively benign clinical course and only 9.5% died
within the 1-year follow-up. Around half of the few patients who
died within the 1-year follow-up period reproduced the clinical
course of the pre-ACLF group and developed multiorgan failure.
In contrast, hypovolemic shock was reported as the main cause
of death in only 5% of cases.
In contrast, patients with pre-ACLF developed AD in the
context of more intense systemic inflammation, which further
increased with ACLF development during follow-up. These
patients differed significantly from patients with SDC in many
other features reported at enrollment, clearly supporting that
they were in a pre-ACLF stage. They exhibited a significantly
higher prevalence of liver failure, liver dysfunction, renal
dysfunction, ascites, encephalopathy and bacterial infections
and significantly worse prognostic scores than patients with SDC
and UDC.852 Journal of Hepatology 2The median time between the onset of decompensated
cirrhosis to liver transplantation or death, which covers
the complete phase of clinically decompensated cirrhosis,
was remarkably shorter in patients in the pre-ACLF group
(12 months) than in those with SDC (20 months), indicating an
accelerated clinical course of the decompensated phase of the
disease towards death in patients with pre-ACLF.
Finally, the clinical course during the first 3-month period
prior to admission, as estimated by the prevalence of ascites,
encephalopathy and bacterial infections, was significantly more
unstable in the pre-ACLF group than in the SDC group. This
finding suggests that patients with pre-ACLF were already more
severely ill than patients with SDC months before reaching the
pre-ACLF status. We presume that the intensity of systemic
inflammation during this period was probably sufficient to
induce this frequent development of complications requiring
hospital admission, but not enough to reach the critical threshold
beyond which ACLF develops.15 Therefore, pre-ACLF should be
suspected in patients hospitalized for AD with prior unstable
clinical course, very high levels of inflammatory markers and
liver failure or liver or kidney dysfunction. Unfortunately, we
were unable to design new specific tools that improve the ac-
curacy of the CLIF-C AD and MELD-sodium scores for predicting
ACLF development.
Patients with UDC shared many characteristics with patients
with pre-ACLF and SDC. Like patients with pre-ACLF, they pre-
sented clinical course instability within the 3-month period prior
to and after enrollment. However, they did not present severe
systemic inflammation at enrollment or a clear increase of
systemic inflammation level during follow-up. This probably
explains the lack of development of ACLF in this group of
patients. A second important finding in patients with UDC was
their significantly higher prevalence of features suggestive of
severe portal hypertension. This finding supports that the second
major pathophysiological mechanism of AD is likely related to
changes in portal hypertension.
Therefore, the most severe course of AD corresponds to pa-
tients with pre-ACLF who develop rapid progression of systemic
inflammation leading to ACLF development and death. The sec-
ond course corresponds to patients with UDC, who have an
increased incidence of complications related to severe portal
hypertension, such as circulatory dysfunction at enrollment,
increased incidence of gastrointestinal hemorrhage and TIPS
placement during the 6-month observational period and higher
mortality due to hypovolemic shock. However, since the grade of
systemic inflammation did not progress to the critical threshold
level to induce extrahepatic organ failure, only a minority of
patients with UDC developed ACLF. Consequently, they lived
longer than patients with pre-ACLF. Finally, the third course of
AD, which is by far the most frequent, corresponds to patients
with SDC and is likely the consequence of a slow progression of
these 2 pathophysiological mechanisms, leading to a relatively
benign course and much longer survival.
This hypothesis is further supported by our findings showing
that ascites, which is the complication associated with the most
extensive organ dysfunction (liver, kidney, heart and systemic
circulation),16,17 was associated with the most intense systemic
inflammation in comparison with hepatic encephalopathy and
gastrointestinal hemorrhage.
Bacterial infections were frequently associated with AD.
Roughly, 1 in every 3-4 patients included in each group were020 vol. 73 j 842–854
infected at the time of AD development. Two mechanisms have
been proposed for this association. The first is that bacterial in-
fections, by increasing the intensity of systemic inflammation,
precipitate the development of AD.2,5,6 The second is that bac-
terial infections would be the consequence of a compensatory
immunomodulatory reaction to systemic inflammation, which
impairs the antibacterial activity of immune cells (immunopar-
alysis).18–20 Our findings suggest that these 2 mechanisms are
not mutually exclusive.
In summary, the PREDICT study suggests that AD in cirrhosis
is a clinical condition with 3 different courses and 2 major
pathophysiological mechanisms. Pre-ACLF is predominantly
related to rapid progression of systemic inflammation, ACLF
development and an extremely high short-term mortality rate.
UDC occurs in the context of rapid progression of portal hyper-
tension and is associated with a less severe clinical course and
lower short-term mortality. Finally, both mechanisms progress
slowly in SDC, and patients follow a relatively benign course with
longer survival. Predicting the outcome of patients who present
with AD is a major future research challenge.
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